Compared to control group participants with HbA1c >9.0%, this large reduction is similar to findings observed in trials that intensified therapy with additional medications in T1D and insulin-treated T2D with poorly controlled diabetes.1,6–11 Thus, we demonstrated that rtCGM has similar glycemic benefits compared to additional pharmacotherapy by empowering patients and clinicians, while eliminating the downsides of adding further medications. The gene discussed is INS; the disease is type 2 diabetes mellitus.